Blog

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

The Universitat Autònoma de Barcelona (UAB) and Pharmacelera have reached an agreement to perform a research project in the area of Parkinson based on the work led by Dr. Salvador Ventura and developed at Institut de Biotecnologia i Biomedicina (IBB). PharmScreen®, Pharmacelera’s flagship software, will be used to perform screening campaigns in huge virtual libraries…

Pharmacelera participates in the SME Instrument Phase I program

Pharmacelera has been awarded an SME Phase I grant from the European Commission for its MolPredict project. The EU received 2009 requests in the call where Pharmacelera submitted its proposal and it decided to support 257 small and medium-sized companies (SMEs) from 31 countries (a 12.8% acceptance rate) who aim to get their innovations faster…

Agreement with CNIO for drug discovery in oncology

The Spanish National Research Centre (CNIO) is a Spanish public institution focused on the research, diagnosis and treatment of cancer. The CNIO is positioned within the top 10 ranking of research centres dedicated to cancer research worldwide (Scimago; Nature Index) and covers the whole R+D+I process, from basic up to clinical research to translate their…

Blog

Agreement with Universitat Autònoma de Barcelona (UAB) in drug discovery for Parkinson disease

Empowering Biotechnology sector in the Bioregion of Catalonia

Pharmacelera participates in the SME Instrument Phase I program

Agreement with CNIO for drug discovery in oncology

Follow us!